Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Crystal form of ribociclib succinate as well as preparation method and application thereof

A technology of monosuccinate and ribociclib, applied in the field of medicine, can solve the problems of high equipment requirements, large residual risk of solvents, and unsuitable for industrial production.

Inactive Publication Date: 2020-09-29
ANLITE SHANGHAI PHARMA TECH CO LTD +2
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

WO2018051280 discloses a method for preparing amorphous ribociclib monosuccinate, which is obtained by dissolving ribociclib monosuccinate in dichloromethane and methanol and then spray-drying. This method requires high equipment. It is not suitable for industrial production, and there is a large risk of solvent residue in the amorphous prepared by this method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal form of ribociclib succinate as well as preparation method and application thereof
  • Crystal form of ribociclib succinate as well as preparation method and application thereof
  • Crystal form of ribociclib succinate as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0120] The present invention provides a method for preparing the above-mentioned crystal form AZT-XXIII. The preparation method comprises: salting the compound of formula (I) and succinic acid in methanol, suction filtration, and drying the filter cake in vacuum. The temperature of the vacuum drying is 25-40°C, preferably 35°C. The compound of formula (I) is a solid compound of formula (I) in any form.

[0121] Crystal form AZT-XXIV and its preparation method

[0122] The crystal form AZT-XXIV provided by the present invention has characteristic peaks in its X-ray diffraction pattern at 2θ values ​​of 8.3°±0.2°, 11.6°±0.2°, 17.7°±0.2° and 20.3°±0.2°.

[0123] Furthermore, the crystal form AZT-XXIV provided by the present invention has an X-ray diffraction pattern with 2θ values ​​of 10.9°±0.2°, 12.7°±0.2°, 14.9°±0.2°, 18.0°±0.2°, 18.9 There are characteristic peaks at °±0.2°, 19.1°±0.2°, 19.4°±0.2°, 19.8°±0.2°, 21.5°±0.2°, 22.7°±0.2°.

[0124] Furthermore, the X-ray diffrac...

Embodiment 1

[0184] Embodiment 1: Preparation of crystal form AZT-XXIII

[0185] Weigh 0.5 g of succinic acid and dissolve it in 30 mL of methanol, weigh 2 g of the compound of formula (I) and suspend it in 30 mL of methanol, add the methanol solution of succinic acid dropwise, filter, and dry the filter cake under vacuum at 40°C to obtain a solid. The obtained solid is the monosuccinate salt form XXIII of the compound of formula (I).

[0186] Carry out XRPD test to the obtained solid, its X-ray powder diffraction pattern is as follows figure 1 As shown, the specific data are shown in Table 1; the obtained solid is tested by TGA, and its spectrogram is as follows figure 2 As shown, there is about 1.5% weight loss when heated to 100°C, which is anhydrous; DSC test is carried out on the obtained solid, and its spectrum is as follows image 3 As shown, the melting point is 181.7°C; 1 H-NMR test, the spectrum is basically as Figure 4 Shown, is monosuccinate.

[0187] Table 1

[0188] ...

Embodiment 2

[0189] Embodiment 2: Preparation of crystal form AZT-XXIV

[0190] Weigh 20 mg of AZT-XXIII in the above Example 1, dissolve in 2 mL of N-methylpyrrolidone / acetone (1:5, v / v) mixed solvent, make a slurry, filter, and vacuum-dry the filter cake at 35°C to obtain a solid, The obtained solid is the monosuccinate salt crystal form AZT-XXIV of the compound of formula (I).

[0191] Carry out XRPD test to the obtained solid, its X-ray powder diffraction pattern is as follows Figure 5 As shown, the specific data are shown in Table 2; the obtained solid is tested by TGA, and its spectrogram is as follows Figure 6 As shown, it has a weight loss of about 7.9% when heated to 145 °C; the resulting solid is subjected to DSC testing, and its spectrogram is as follows Figure 7 As shown, there is an exothermic peak at 131.5°C, an endothermic peak at 132.9°C, and a melting point of 185.8°C.

[0192] Table 2

[0193] 2θ strength 8.3 68.3％ 10.9 42.5％ 11.6 54.1％ ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a crystal form of ribociclib succinate as well as a preparation method and application thereof. Specifically, the invention provides a plurality of new crystal forms of ribociclib succinate and a preparation method thereof, and the new crystal forms have excellent solubility and other properties.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a crystal form of ribociclib monosuccinate and a preparation method and application thereof. Background technique [0002] Ribociclib (Ribociclib, trade name: KISQALI), developed by Swiss Novartis Pharmaceuticals Co., Ltd., is a cyclin-dependent kinase 4 / 6 (CDK4 / 6) inhibitor, used for the treatment of hormone receptor positive, human epidermis Growth factor receptor-2 negative (HR+ / HER2-) postmenopausal women with advanced or metastatic breast cancer. The chemical name of ribociclib is 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxy Acid dimethylamide, its molecular structure is as shown in formula (I): [0003] [0004] KISQALI uses ribociclib monosuccinate, but there are few studies on ribociclib monosuccinate. [0005] WO2012064805 discloses a hydrate crystal form and an anhydrous crystal form of the monosuccinate salt of the compound of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04C07C55/10C07C51/41A61K31/519A61P35/00
CPCA61P35/00C07B2200/13C07C51/412C07C55/10C07D487/04
Inventor 尚婷婷张良
Owner ANLITE SHANGHAI PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com